Anti-Beta2-Glycoprotein-1 IgG ELISA Kit


The anti-beta2-glycoprotein 1 IgG (beta2GP1) test is a quantitative/qualitative enzyme-linked immunosorbent assay (ELISA) for the detection of the IgG class of autoantibodies specific for beta2GP1 antigen in human serum or citrate/EDTA anticoagulated plasma. It is intended to aid in the assessment of thrombotic risk in patients with autoimmune disease associated with thrombotic disorders such as primary antiphospholipid syndrome or secondary to systemic lupus erythematosus. It is not definitive in isolation. Autoantibody levels represent one parameter in a multicriterion diagnostic process. The Eagle Biosciences Anti-beta2-glycoprotein 1 IgG ELISA Assay Kit is for Research Use Only.

Anti-Beta2-Glycoprotein 1 IgG ELISA Kit

Anti-Beta2-Glycoprotein-1 IgG ELISA Kit Developed and Manufactured by Svar Life Science

Size: 1×96 wells
Sensitivity: See Package Insert
Dynamic Range: Cut-off
Incubation Time: 2 hours
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Names: Anti-Beta 2 GP1 IgG ELISA, Human Anti-Beta 2 Glycoprotein 1 IgG ELISA,
For Research Use Only

Controls Included

Sample Collection and Storage: The assay is recommended for serum/plasma (citrate or EDTA anticoagulated) samples; do not use lipaemic, haemolysed, icteric or turbid samples. Thoroughly mix thawed samples before assay and avoid repeated freeze/thawing. Do not heat-inactivate samples, this may yield false positive results. Samples may be stored undiluted or at 1:101 dilution in diluted Sample Diluent 2 at -20° C or 2-8° C for four weeks.
Reference Range:
<10U/mL = Negative ≥10-15U/mL = Equivocal Result >15U/mL = Positive
It is recommended that each laboratory establish their own normal range.

Assay Principle

In this Anti-Beta2-Glycoprotein-1 IgG ELISA Kit, wells of the microtitre strips are coated with highly purified human β2GP1 antigen. During the first incubation, specific autoantibodies in diluted serum or plasma bind to the antigen-coated surface. The wells are then washed to remove unbound components. In the second incubation, the Conjugate, enzyme-labeled antibodies to human IgG, binds any surface-bound autoantibodies. After further washing, specific autoantibodies are traced by incubation with the Substrate. Addition of Stop Solution terminates the reaction, resulting in a colored end-product. The amount of Conjugate bound is measured in absorbance units. In the qualitative protocol, the amount of Conjugate bound by the sample is compared with that bound by the Reference Control. In the quantitative protocol, the concentration of anti-β2GP1 autoantibody can be estimated by interpolation from a dose-response curve based on Standards formulated from a high titer plasma and assigned arbitrary units.

Related Products

Anti Beta 2 Glycoprotein 1 Screen ELISA Assay Kit
Anti-Beta-2 GP-I Screen ELISA
Anti-GP2 IgA ELISA Kit

Additional Information

Assay Background

β2-glycoprotein 1 (β2GP1), or apolipoprotein H, is a plasma glycoprotein that circulates at approximately 200μg/mL1. It is associated with plasma lipoproteins, in particular very low-density lipoprotein, and may regulate hemostatic actions occurring on the lipoprotein surface2. β2GP1 has been shown to inhibit the intrinsic coagulation pathway via inhibition of Factor XII activation on negatively charged surfaces, and is the dominant antigen for antiphospholipid antibodies (APAs) in patients with anti-phospholipid syndrome3. The presence of APAs such as anti-cardiolipin antibodies is associated with venous and arterial thrombosis, recurrent spontaneous abortions and thrombocytopenia. Anti-cardiolipin antibodies are also present in response to a variety of infections and certain drug treatments. APAs associated with infections are usually transient and not associated with thromboembolic complications; APAs in autoimmune disease are often associated with thromboembolic disease4. Although the mechanism of APA binding is poorly understood, it has been demonstrated that APAs may bind directly to phospholipid or via a protein co-factor, most commonly β2GP1. β2GP1 is often included in anti-cardiolipin assays to ensure the detection of both β2GP1-dependent and β2GP1-independent antibodies. β2GP1 dependent APAs tend to be associated with autoimmune disease; β2GP1-independent APAs tend to be associated with infection3,4. A number of studies have demonstrated that detection of β2GP1 antibodies, in conjunction with anticardiolipin measurement, is important in defining the thrombotic risk associated with APAs. β2GP1 IgG antibodies are more closely associated with thrombosis in patients with a history of antiphospholipid antibody-associated diseases than anti-cardiolipin antibodies5-8.


Product Manual